hepat
c
viru
hcv
affect
million
peopl
worldwid
one
import
pathogen
caus
morbid
mortal
difficulti
erad
hcv
attribut
limit
treatment
option
viru
unsatisfactori
efficaci
even
effect
regimen
pegyl
interferon
ifn
ribavirin
combin
efficaci
limit
less
half
patient
treat
given
situat
develop
safe
effect
therapi
one
goal
rna
interfer
rnai
process
gene
silenc
initi
rna
potenc
specif
rnai
rapidli
becom
power
tool
basic
research
analyz
gene
function
potenti
therapeut
applic
recent
success
suppress
variou
human
pathogen
rnai
report
includ
human
immunodefici
virus
polioviru
influenza
viru
sever
acut
respiratori
syndrom
sar
viru
hepat
b
viru
hbv
research
report
appropri
design
small
interf
rna
sirna
target
hcv
genom
rna
effici
specif
suppress
hcv
replic
vitro
test
sirna
design
target
region
identifi
effect
target
upstream
translat
initi
codon
furthermor
transfect
vector
express
sirna
effect
synthet
sirna
suppress
hcv
replic
studi
explor
possibl
effici
deliveri
express
sirna
may
effect
suppress
elimin
hcv
replic
deliveri
sirna
vivo
may
effect
silenc
viral
protein
express
liver
report
hcv
replic
suppress
vitro
recombin
retroviru
adenoviru
vector
express
short
hairpin
rna
shrna
deliveri
adenoviru
vector
mice
vivo
specif
inhibit
viral
protein
synthesi
liver
retro
pack
cell
clontech
palo
alto
ca
usa
maintain
dulbecco
modifi
minim
essenti
medium
sigma
st
loui
mo
usa
supplement
fetal
calf
serum
maintain
cell
line
carri
hcv
replicon
wako
osaka
japan
ad
cultur
medium
final
concentr
hcv
replicon
plasmid
construct
construct
viru
strain
genotyp
express
chimer
report
protein
firefli
luciferas
fluc
neomycin
phosphotransferas
express
fluc
blasticidin
bsd
resist
gene
respect
fig
replicon
rna
synthesi
transfect
protocol
describ
previous
design
construct
sirna
vector
describ
briefli
five
sirna
target
hcv
rna
test
effici
inhibit
hcv
replic
effect
sequenc
target
nucleotid
posit
though
use
present
studi
construct
dna
cassett
oligonucleotid
insert
synthes
contain
loop
sequenc
aag
flank
sens
antisens
sirna
sequenc
fig
insert
immedi
downstream
human
promot
avoid
problem
transcrib
shrna
instabl
dna
strand
aris
tight
palindrom
structur
sever
point
mutat
retain
complet
silenc
activ
shrna
introduc
sens
strand
shrna
sequenc
refer
control
plasmid
express
shrna
direct
toward
diseas
gene
mutant
gene
normal
express
previous
describ
sequenc
specif
activ
prior
construct
viru
vector
test
silenc
effici
five
shrna
construct
differ
length
cover
target
sequenc
fig
target
sequenc
nucleotid
respect
transfect
shrna
construct
show
shrna
longer
target
sequenc
better
suppress
effect
fig
therefor
use
abbrevi
follow
studi
express
cassett
insert
stuihindiii
site
retroviru
vector
clontech
construct
fig
plasmid
transfect
packag
cell
retro
pack
cultur
supernat
filter
ad
onto
cell
polybren
cell
line
stabli
express
shrna
establish
cultur
presenc
recombin
adenovirus
express
shrna
construct
use
adenoviru
express
vector
kit
takara
otsu
japan
express
dna
cassett
insert
swai
site
paxcw
construct
adenovirus
propag
accord
manufactur
protocol
fig
multipl
infect
moi
use
standard
infect
dose
adenoviru
moi
stand
ratio
infecti
viru
particl
number
cell
infect
moi
repres
equival
dose
introduc
one
infecti
viru
particl
everi
host
cell
present
cultur
invitrogen
carlsbad
ca
usa
contain
five
copi
consensu
interferon
stimul
respons
element
isr
motif
upstream
fluc
gene
invitrogen
lack
enhanc
element
use
background
determin
invitrogen
use
empti
vector
mock
transfect
promega
madison
wi
usa
express
renilla
luciferas
protein
use
normal
transfect
effici
plasmid
pegfpneo
invitrogen
use
monitor
percentag
transduc
cell
total
cellular
rna
extract
cultur
cell
liver
tissu
use
isogen
nippon
gene
tokyo
japan
total
cellular
rna
use
gener
cdna
sampl
use
superscript
ii
invitrogen
mrna
express
level
measur
use
light
cycler
pcr
detect
system
roch
mannheim
germani
light
cycler
fast
start
dna
master
sybr
green
mix
roch
luciferas
activ
measur
use
luminomet
lumat
promega
luciferas
assay
system
promega
report
assay
system
promega
total
cellular
rna
separ
denatur
gel
electrophoresi
transfer
nylon
membran
membran
hybrid
probe
specif
replicon
sequenc
subsequ
probe
specif
signal
detect
chemiluminesc
reaction
use
digoxigenin
luminesc
detect
kit
roch
visual
roch
western
blot
total
cell
lysat
separ
nupag
invitrogen
blot
onto
immobilon
pvdf
membran
roch
membran
incub
monoclon
antibodi
specif
biodesign
saco
usa
virogen
watertown
usa
sigma
detect
chemiluminesc
reaction
bm
chemiluminesc
blot
substrat
pod
roch
replicon
transfect
cell
luciferas
activ
cell
lysat
measur
serial
correct
transfect
effici
valu
divid
luciferas
activ
h
transfect
cell
transfect
replicon
cultur
presenc
bsd
invitrogen
cell
coloni
appear
week
cultur
count
transcrib
rna
transfect
cell
naiv
cell
subsequ
infect
cultur
supernat
transfect
cell
subject
sirna
drug
treatment
replic
level
quantifi
realtim
use
primer
target
region
sens
gac
aga
gcc
tga
gtc
antisens
tgc
tgg
agg
gct
tct
transgen
mice
induc
express
mrna
hcv
structur
protein
nucleotid
creloxp
switch
system
transgen
contain
hcv
share
target
sequenc
although
transgen
mous
previous
report
express
higher
level
viral
protein
express
level
viral
core
protein
mice
modest
similar
liver
hcv
patient
thu
chose
mice
present
studi
mice
infect
control
combin
axcancr
express
cre
recombinas
three
day
infect
mice
kill
hcv
core
protein
liver
measur
describ
balbc
mice
maintain
anim
care
facil
tokyo
medial
dental
univers
transgen
mice
tokyo
metropolitan
institut
medic
scienc
anim
care
accord
institut
guidelin
review
board
univers
approv
experiment
anim
studi
experi
approv
institut
anim
studi
committe
amount
hcv
core
protein
liver
tissu
mice
measur
fluoresc
enzym
immunoassay
feia
slight
modif
briefli
monoclon
antibodi
use
first
antibodi
solid
phase
antibodi
conjug
horseradish
peroxidas
second
antibodi
feia
detect
littl
pgml
recombin
protein
content
hcv
core
protein
liver
sampl
normal
total
protein
content
express
pgmg
total
protein
liver
tissu
frozen
optim
cut
temperatur
otc
compound
tissu
tek
sakura
finetechn
tokyo
japan
section
thick
fix
solut
aceton
methanol
min
wash
salin
pb
subsequ
section
incub
igg
fraction
core
rabbit
polyclon
antibodi
block
buffer
antialbumin
rabbit
polyclon
antibodi
dako
cytom
glostrup
denmark
pb
overnight
section
incub
secondari
antibodi
igg
invitrogen
igg
sigma
h
room
temperatur
fluoresc
observ
use
fluoresc
microscop
statist
analys
perform
use
student
less
consid
statist
signific
retroviru
vector
propag
use
infect
cell
cell
line
establish
constitut
express
respect
differ
cell
morpholog
growth
rate
cell
data
shown
hcv
replicon
transfect
naiv
cell
electropor
naiv
cell
initi
luciferas
activ
h
decreas
temporarili
repres
decay
transfect
replicon
rna
increas
h
h
demonstr
de
novo
synthesi
hcv
replicon
rna
contrast
transfect
cell
result
decreas
initi
luciferas
activ
reach
background
h
fig
similarli
transfect
replicon
cell
bsd
select
yield
numer
coloni
naiv
coloni
cell
line
coloni
transfect
express
yield
obvious
fewer
coloni
five
coloni
indic
reduct
coloni
form
unit
fig
differ
shape
growth
viabil
cell
express
shrna
result
indic
cell
express
shrna
follow
retroviru
transduct
acquir
resist
hcv
replic
investig
subsequ
effect
recombin
adenoviru
vector
express
shrna
use
separ
infect
cell
intern
luciferas
activ
measur
sequenti
fig
caus
continu
suppress
hcv
rna
replic
six
day
postinfect
luciferas
activ
fell
background
level
contrast
luciferas
activ
cell
infect
show
signific
chang
compar
untreat
cell
fig
dimethylthiazol
carboxymethoxyphenyl
sulfophenyl
tetrazolium
mt
assay
show
signific
differ
cell
infect
recombin
adenoviru
uninfect
cell
fig
northern
blot
analysi
cell
harvest
day
infect
adenoviru
moi
rna
kb
detect
untreat
cell
cell
infect
diminish
substanti
follow
infect
fig
densitometri
show
intracellular
level
replicon
rna
cell
correl
well
intern
luciferas
activ
similarli
western
blot
cell
harvest
day
infect
adenoviru
level
hcv
protein
translat
hcv
replicon
decreas
follow
infect
fig
result
indic
decreas
luciferas
activ
due
specif
suppress
effect
shrna
express
hcv
genom
rna
viral
protein
due
effect
caus
deliveri
shrna
toxic
adenoviru
vector
report
rna
may
induc
gene
isg
respons
caus
instabl
mrna
translat
suppress
protein
apoptot
cell
death
therefor
examin
effect
plasmid
adenovirus
activ
isg
express
cell
plasmid
control
plasmid
pegfpneo
transfect
cell
plasmid
adenoviru
luciferas
activ
measur
day
activ
significantli
chang
cell
shrna
plasmid
transfect
fig
similarli
express
level
mxa
protein
significantli
chang
transfect
vector
fig
result
demonstr
shrna
use
present
studi
lack
induct
isg
respons
form
express
plasmid
adenoviru
vector
effect
adenovirus
confirm
use
viru
cell
cultur
system
transfect
sirna
cell
result
substanti
decreas
intracellular
hcv
rna
control
sirna
show
effect
fig
similarli
infect
cell
specif
suppress
express
hcv
rna
fig
effect
shrna
express
express
viral
structur
protein
vivo
investig
use
condit
hcv
mice
adenovirus
inject
mice
combin
axcancr
adenoviru
express
cre
dna
recombinas
mice
kill
fourth
day
inject
hepat
express
hcv
core
protein
measur
express
amount
core
protein
pgmg
pgmg
mice
respect
express
amount
significantli
lower
mice
inject
pgmg
p
fig
similarli
induc
express
hcv
core
protein
detect
immunohistochemistri
infect
liver
tissu
fig
stain
host
cellular
protein
albumin
obvious
differ
liver
infect
fig
express
level
two
isg
liver
tissu
significantli
differ
individu
without
inject
adenoviru
vector
fig
result
indic
specif
shrna
silenc
hcv
structur
protein
express
liver
requir
achiev
high
effici
use
rnai
select
target
sequenc
suscept
rnai
ii
persist
sirna
activ
iii
effici
vivo
deliveri
sirna
cell
use
shrna
sequenc
deriv
highli
effici
sirna
construct
shrna
express
cassett
show
competit
effect
synthet
sirna
fig
cassett
allow
extend
rnai
also
enabl
use
vector
viru
vector
shown
result
retroviru
vector
express
could
stabli
transduc
cell
express
shrna
cell
acquir
protect
hcv
subgenom
replic
fig
adenoviru
vector
express
result
suppress
hcv
subgenom
protein
express
around
three
log
almost
background
level
fig
consist
result
obtain
use
hcv
cell
cultur
fig
importantli
demonstr
effect
viral
protein
express
liver
use
condit
transgen
mous
model
fig
result
suggest
effici
deliveri
sirna
could
effect
hcv
infect
vivo
obstacl
appli
sirna
technolog
treat
viru
infect
virus
prone
mutat
replic
hcv
continu
produc
mutat
viral
strain
escap
immun
defens
mechan
even
singl
patient
circul
hcv
popul
compris
larg
number
close
relat
hcv
sequenc
variant
call
quasispeci
therefor
sirna
target
sequenc
hcv
genom
report
other
may
vari
consider
among
differ
hcv
genotyp
even
among
strain
genotyp
shrna
sequenc
target
hcv
rna
conserv
region
among
variou
hcv
isol
addit
structur
constraint
term
requir
direct
intern
ribosom
entri
translat
viral
protein
might
permit
evolut
escap
mutat
preliminari
result
shown
suppress
replic
hcv
genotyp
replicon
extent
hcv
replicon
although
sirna
techniqu
reli
high
degre
specif
sever
studi
report
effect
may
result
induct
isg
respons
effect
may
mediat
activ
protein
kinas
receptor
possibl
recent
identifi
rna
helicas
remain
determin
whether
effect
gener
induc
everi
sirna
construct
sledz
et
al
report
transfect
two
sirna
induc
cellular
interferon
respons
bridg
et
al
report
plasmid
induc
interferon
respons
transfect
synthet
sirna
specul
effect
interferon
system
might
construct
depend
plasmid
adenovirus
activ
isg
respons
vitro
fig
b
vivo
fig
preliminarili
detect
phosphoryl
pkr
western
blot
found
appar
increas
data
shown
result
indic
target
sequenc
structur
suffici
specif
silenc
target
gene
without
elicit
interferon
respons
besid
canon
action
sirna
cleavag
target
mrna
sirna
could
act
suppress
translat
initi
mrna
could
mediat
transcript
gene
silenc
regard
experi
difficult
differenti
analyz
effect
sirna
individu
site
action
effect
sirna
concomitantli
destabil
target
mrna
lead
appar
decreas
mrna
transcript
effici
safeti
gene
transfer
method
key
determin
clinic
success
gene
therapi
unresolv
problem
sever
report
deliveri
sirna
vector
cell
vivo
howev
gene
deliveri
method
safe
enough
appli
clinic
therapeut
current
develop
adenoviru
vector
one
commonli
use
carrier
human
gene
therapi
present
result
demonstr
adenovir
deliveri
shrna
effect
block
hcv
replicationin
vitro
viru
protein
express
vivo
adenoviru
vector
sever
advantag
effici
deliveri
transgen
vitro
vivo
natur
hepatotrop
administ
vivo
specif
block
express
hcv
structur
protein
condit
transgen
mous
express
protein
current
adenoviru
vector
may
caus
inflammatori
reaction
target
organ
howev
produc
neutral
antibodi
make
repeat
administr
difficult
problem
may
overcom
improv
construct
viru
vector
attenu
immunogen
develop
carrier
gene
deliveri
conclus
result
demonstr
effect
feasibl
sirna
express
system
effici
adenoviru
express
shrna
target
hcv
suggest
deliveri
express
sirna
hepatocyt
may
elimin
viru
approach
might
provid
potenti
effect
futur
therapeut
option
hcv
infect
